Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

and administrative (SG&A) expenses are expected to be $240 to $260 million.

Conference Call and WebcastViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and all other operational results of the first quarter on May 1, 2013 at 9:00 a.m. Eastern. To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com.  Windows Media or Real Player will be needed to access the webcast.  An audio archive will be available at the same address until May 15, 2013.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing
and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at '/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Participate in Two December Healthcare Investor Conferences
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... 2014 Sapphire Energy, Inc. , a ... appointment of biotechnology veteran James Levine as ... Levine replaces Cynthia ,CJ, Warner, who is stepping down ... of the company,s board of directors. "The ... deliver commercial scale algae-based fuels has been tremendous, from ...
(Date:7/28/2014)... Research and Markets has announced ... 2014-2018" report to their offering. ... biology covers the designing and engineering of completely new ... redesigning of natural biological systems that provide improved and ... of extreme genetic engineering because it not only alters ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health , ... announced the hire of Brad Towle as ... be responsible for driving the company,s sales growth, customer ... in healthcare, and specifically his past role in the ... the company at this pivotal time in the industry," ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... 22 Fred Hutchinson Cancer Research Center,s,stem-cell transplant ... was,one of only two transplant programs nationwide that ... donor transplants, according,to an independent report that assessed ... The Center for International Blood ...
... in Genetic Engineering News for delivering the promise of safety without ... ... (PRWEB) January 22, 2009 -- InVitria,s product line was featured in ... 15, 2009 pp 32-34). The article, entitled Culture Media Underlies ...
... SAN DIEGO, Jan. 22 Axikin Pharmaceuticals, Inc., ... small molecule therapeutics for respiratory and inflammatory diseases, ... its Series A stock. The financing was ... Additional investors include Mitsui & Co. Venture ...
Cached Biology Technology:Transplant Program Tops in Expected One-Year Survival Rate 2InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication 2Axikin Pharmaceuticals Spins out of Actimis 2Axikin Pharmaceuticals Spins out of Actimis 3
(Date:7/29/2014)... San Francisco is the first to show that while ... cellular aging, these negative effects may be reduced by ... , "The study participants who exercised, slept well and ... who didn,t maintain healthy lifestyles, even when they had ... PhD, assistant professor in the department of psychiatry at ...
(Date:7/28/2014)... a circulatory problem of the legs called peripheral vascular ... surgery in serious cases. This disease can lead to ... , At The University of Texas Health Science Center ... preventative treatment in a mouse model of the disease ... Their proof-of-concept study appears in the journal Cell ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2
... N.Y. Despite the fact that congenital heart ... the United States, pediatric cardiology receives relatively little attention ... volume entitled My Heart vs. the Real World ... Through striking black-and-white photographs and interviews with CHD ...
... risk by 72% in male smokers who had high ... effect on those who had low dietary vitamin C ... Journal of Nutrition. Previous studies had suggested that ... studies vitamin E seemed to protect against various infections. ...
... straight line may be the shortest distance between two ... path to follow. Thats particularly true when terrain ... have developed a mathematical model showing that a zigzag ... go up or down steep slopes. I think ...
Cached Biology News:New book gives a human face to children with congenital heart disease 2In the race to the top, zigzagging is more efficient than a straight line 2
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: